+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Angina (Angina Pectoris) - Pipeline Review, H2 2019

  • ID: 4866519
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 73 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Angionetics Inc
  • Ark Therapeutics Ltd
  • Caladrius Biosciences Inc
  • Hemostemix Inc
  • ID Pharma Co Ltd
  • Signal Pharma Ltd
  • MORE
Angina (Angina Pectoris) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Angina - Pipeline Review, H2 2019, provides an overview of the Angina (Cardiovascular) pipeline landscape.

Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Angina - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Angina (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 3, 1, 1 and 3 respectively.

Angina (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Angina (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Angina (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Angina (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Angina (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Angina (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Angionetics Inc
  • Ark Therapeutics Ltd
  • Caladrius Biosciences Inc
  • Hemostemix Inc
  • ID Pharma Co Ltd
  • Signal Pharma Ltd
  • MORE
Introduction
Report Coverage
Angina (Angina Pectoris) - Overview
Angina (Angina Pectoris) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Angina (Angina Pectoris) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Angina (Angina Pectoris) - Companies Involved in Therapeutics Development
Angionetics Inc
Ark Therapeutics Ltd
Caladrius Biosciences Inc
G. Pohl-Boskamp GmbH & Co KG
Hemostemix Inc
ID Pharma Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Kuhnil Pharmaceutical Co Ltd
Milestone Pharmaceuticals Inc
Signal Pharma Ltd
TSH Biopharm Corporation Ltd
VasThera Research Institute
XyloCor Therapeutics Inc
Angina (Angina Pectoris) - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alferminogene tadenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etripamil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ivabradine hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KI-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitroglycerin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranolazine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Angina - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PRDX2 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Angina (Angina Pectoris) - Dormant Projects
Angina (Angina Pectoris) - Discontinued Products
Angina (Angina Pectoris) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Angina (Angina Pectoris), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Products under Development by Companies, H2 2019
Table 4: Number of Products by Stage and Target, H2 2019
Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
Table 6: Number of Products by Stage and Route of Administration, H2 2019
Table 7: Number of Products by Stage and Molecule Type, H2 2019
Table 8: Angina (Angina Pectoris) - Pipeline by Angionetics Inc, H2 2019
Table 9: Angina (Angina Pectoris) - Pipeline by Ark Therapeutics Ltd, H2 2019
Table 10: Angina (Angina Pectoris) - Pipeline by Caladrius Biosciences Inc, H2 2019
Table 11: Angina (Angina Pectoris) - Pipeline by G. Pohl-Boskamp GmbH & Co KG, H2 2019
Table 12: Angina (Angina Pectoris) - Pipeline by Hemostemix Inc, H2 2019
Table 13: Angina (Angina Pectoris) - Pipeline by ID Pharma Co Ltd, H2 2019
Table 14: Angina (Angina Pectoris) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Table 15: Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2019
Table 16: Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals Inc, H2 2019
Table 17: Angina (Angina Pectoris) - Pipeline by Signal Pharma Ltd, H2 2019
Table 18: Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, H2 2019
Table 19: Angina (Angina Pectoris) - Pipeline by VasThera Research Institute, H2 2019
Table 20: Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, H2 2019
Table 21: Angina (Angina Pectoris) - Dormant Projects, H2 2019
Table 22: Angina (Angina Pectoris) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 23: Angina (Angina Pectoris) - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Angina (Angina Pectoris), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Targets, H2 2019
Figure 4: Number of Products by Stage and Targets, H2 2019
Figure 5: Number of Products by Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Angionetics Inc
  • Ark Therapeutics Ltd
  • Caladrius Biosciences Inc
  • G. Pohl-Boskamp GmbH & Co KG
  • Hemostemix Inc
  • ID Pharma Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Kuhnil Pharmaceutical Co Ltd
  • Milestone Pharmaceuticals Inc
  • Signal Pharma Ltd
  • TSH Biopharm Corporation Ltd
  • VasThera Research Institute
  • XyloCor Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll